Survivin, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-Survivin, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Survivin, Human |
| Clone | REA459 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | Vio R667 conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Intracellular flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Survivin Antibody, anti-human, Vio® R667, REAfinity™. Clone REA459 recognizes the human survivin antigen, a member of the inhibitor of apoptosis (IAP) family. Survivin is also known as baculoviral IAP repeat-containing protein 5 (BIRC5) or apoptosis inhibitor 4 (API4). The survivin protein inhibits caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. Expression of survivin is highly regulated by the cell cycle and is only expressed in the G2-M phase. Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. It is expressed highly in most human tumors and fetal tissue, but is completely absent in terminally differentiated cells. Its overexpression has been demonstrated in breast and lung cancer, prostate, gastric, colon, bladder and esophageal carcinomas, osteosarcomas, and lymphomas. Overexpression of survivin was also found to be significantly associated with a poor prognosis and decreased survival rates in oral, breast, and colorectal cancers. | Additional information: Clone REA459 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | BIRC5, API4, EPR-1, IAP4 |
| Gene, Accession # | Gene ID: 332 |
| Catalog # | 130-128-703 |
| Price | $134 |
| Order / More Info | Survivin, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Ambrosini, G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (8): 917-921. | Cheung, C. H. et al. (2013) Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther. 16 (6): 1453-1462. | Fukuda, S. et al. (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 5 (5): 1087-1098. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG